Print Share Email Send Email Your Name (required) ! Example: John Doe Email Address (required) ! Error: Please enter a valid sender email address. Example: firstname.lastname@example.org CC Me Recipient Email Address (required) ! Separate multiple email address with semi-colons (up to 5). Subject Subject for your email. Message (Maximum characters: 1,000) Error: Please enter your name Error: Please enter your email address Error: Please enter a valid recipient email address. Example:email@example.com Thank you! Your email has been sent to: The recipient(s) will receive an email message that includes a link to the selected article. Recipients may need to check their spam filters or confirm that the address is safe. Return to: Send Another Email An error has occurred sending your email(s). Please try again later or contact an administrator at OnlineCustomer_Service@email.mheducation.com. Return to: Twitter Facebook Linkedin Reddit Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Yunus F, Koruth J. Yunus F, & Koruth J Yunus, Fahd, and Jacob Koruth. Critical Analysis of the AFIRE Trial: Rivaroxaban Monotherapy versus Combination Therapy in Patients with Atrial Fibrillation and Stable Coronary Artery Disease. Hurst's the Heart Updates, 16 October 2019. McGraw-Hill, 2019. AccessCardiology. https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=506579§ionid=229608369APA Citation Yunus F, Koruth J. Yunus F, & Koruth J Yunus, Fahd, and Jacob Koruth. (2019). Critical analysis of the afire trial: rivaroxaban monotherapy versus combination therapy in patients with atrial fibrillation and stable coronary artery disease. Fuster V. Fuster V Fuster, Valentin. Hurst's the heart updates. McGraw-Hill. https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=506579§ionid=229608369.MLA Citation Yunus F, Koruth J. Yunus F, & Koruth J Yunus, Fahd, and Jacob Koruth. "Critical Analysis of the AFIRE Trial: Rivaroxaban Monotherapy versus Combination Therapy in Patients with Atrial Fibrillation and Stable Coronary Artery Disease." Hurst's the Heart Updates Fuster V. Fuster V Fuster, Valentin. McGraw-Hill, 2019, https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=506579§ionid=229608369. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Top Critical Analysis of the AFIRE Trial: Rivaroxaban Monotherapy versus Combination Therapy in Patients with Atrial Fibrillation and Stable Coronary Artery Disease by Fahd Yunus, Jacob Koruth Listen + +Update to: Chapter 41: Antiplatelet and Anticoagulant Therapy in Acute Coronary Syndrome, and Chapter 83: Atrial fibrillation, Atrial Flutter, and Atrial Tachycardia Study Summary + +The AFIRE trial assessed the management of patients with AF, stable CAD, and either a history of PCI or CABG at least 1 year before enrollment, or stenosis ≥50% not requiring revascularization. Patients were randomly assigned to receive rivaroxaban (15 mg daily for CrCl ≥50 mg/min, or 10 mg daily for CrCl 15–50 mg/min; n = 1,118) or rivaroxaban plus an antiplatelet agent (either aspirin or a P2Y12 inhibitor; n = 1,118). During follow-up (mean 24 months), the incidence of the primary efficacy outcome (all-cause mortality, MI, stroke, unstable angina, or systemic embolism) was 4.14% per patient-year in the monotherapy group and 5.75% per patient-year in the combination therapy group (HR 0.72; P < 0.001 for noninferiority). The incidence of the primary safety endpoint (ISTH criteria major bleeding) was 1.62% per patient-year in the monotherapy group and 2.76% per patient-year in the combination therapy group (HR 0.59, P = 0.01). Commentary + +Study Strengths: The AFIRE trial was a large, multicenter, randomized clinical study, which had sufficient statistical power to show noninferiority of rivaroxaban monotherapy for the primary efficacy outcome and superiority for the primary safety outcome. The trial was terminated early after an increased rate of all-cause death was reported in the combination therapy group. +Study Limitations: The study was performed in Japan and used the dose of rivaroxaban approved in Japan, which is lowerthan that used used throughout most of the rest of the world. In the combination therapy group, the trust had an open label design such that the choice between aspirin or P2Y12 inhibitor was made by the investigator. +Next Steps/Clinical Perspective: The AFIRE trial builds on the results of previous trials and provides strong evidence to support the clinical use of oral anticoagulation alone without antiplatelet therapy in patients with AF and stable CAD who are at least 1 year on from revascularization. Trial Reference + + + +Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for Atrial Fibrillation with Stable Coronary Disease. N. Engl. J. Med. doi: 10.1056/NEJMoa1904143.